Patients aged 80 and older are often excluded from receiving the standard regimen for acute myeloid leukemia. However, research showed that some patients can tolerate the therapy.
Q1 2024 revenue was $8.8 million, which represents an 18% increase over Q1 2023Total installed base of 347 optical genome mapping (OGM) systems as of Q1 2024, which represents a 34% increase over Q1 ...